Clinical Trials

Ongoing Studies

Celldex - “A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer”

To test the effectiveness of a medication called CDX-011. CDX-011 has been previously studied in patients with melanoma and breast cancer. Here at TTUHSC El Paso, this study is looking to see if CDX-011 helps patients who have triple negative breast cancer that has spread to other parts of the body.

Research type: therapeutic

 

Novartis - “A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment.”

To determine if the study drug, BKM120, can benefit patients when added to standard treatment for patients with advanced breast cancer.

Research type: therapeutic

 

ECOG-ACRIN- E2112 “A Randomized, Double Blind, Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Patients with Hormone Receptor–Positive and HER2–Negative Advanced Breast Cancer.”

To prolong progression-free survival and overall survival, to ameliorate symptoms and improve quality of life. A novel approach to improve efficacy of endocrine therapy while minimizing toxicity.

Research type: therapeutic

Clinical Research Coordinator:

Aleli Campbell
aleli.campbell@ttuhsc.edu
915-215-4809

 

NRG-BR003 – “A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive of High-Risk Node-Negative Triple-Negative Invasive Breast Cancer”

To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the invasive disease-free survival (IDFS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer.

Research type: therapeutic 

 

Alliance A011106 – “ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study”

To determine whether fulvestrant administered for 24 weeks as neoadjuvant endocrine treatment decreases the proportion of endocrine resistant tumors relative to patients treated with anastrozole and to determine whether fulvestrant in combination with anastrozole, administered for 24 weeks as neoadjuvant endocrine treatment, decreases the proportion of endocrine resistant tumors relative to patients treated with anastrozole.

Research type: therapeutic

Clinical Research Coordinator:
Aleli Campbell

aleli.campbell@ttuhsc.edu
915-215-4809

 

Alliance A011202 - “A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy.”

To evaluate whether radiation to the undissected axilla and regional lymph nodes is not inferior to axillary lymph node dissection with radiation to the regional lymph nodes but not to the dissected axilla in terms of invasive breast cancer recurrence-free interval in patients with positive SLN(s) after completion of neoadjuvant chemotherapy.

Research type: therapeutic 

 

SWOG S1207 - "A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer"

To find out whether the drug everolimus (Affinitor®) taken with hormonal therapy is more effective than standard hormonal therapy for patients with breast cancer who have a high risk for cancer recurrence.

Research type: therapeutic

Clinical Research Coordinator:

Aleli Campbell
aleli.campbell@ttuhsc.edu
915-215-4809

 

SWOG 1007 - "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone-responsive and Her2-Negative Breast Cancer according to Recurrence Score (RS)"

To use a test to predict who will benefit from chemotherapy and who is unlikely to benefit so that we can save some patients from the serious side effects and the cost of a course of chemotherapy treatment they don’t need.

Research type: therapeutic

 

 

SWOG 0221- “Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer."

To compare how long women with advanced or metastatic HER2-negative breast cancer live after receiving treatment with capecitabine and ruxolitinib against those who receive capecitabine and placebo.

Research type: therapeutic

 

Propranolol – “A Pilot ‘Window of Opportunity’ Neoadjuvant Study of Propranolol in Breast Cancer”

To determine if the medicine, propranolol, can change the way breast cancer tumors grow and if it can slow down tumor growth.

Research type: therapeutic

 

 

Vitamin B12 – “A Single Arm Phase II Study of Oral Vitamin B12 for the Treatment of Aromatase Inhibitors (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer”

To assess whether daily oral Vitamin B12 decreases average joint pain in women with aromatase inhibitor-associated musculoskeletal symptoms.

Research type: therapeutic

Clinical Research Coordinator:
Aleli Campbell

aleli.campbell@ttuhsc.edu
915-215-4809

 

“Stage and Characteristics of Patients with Newly Diagnosed Breast Cancer at TTUHSC Breast Cancer Clinic El Paso”

To assess the stages at presentation of patients with breast cancer, to assess the characteristics of disease in breast cancer patients, and to compare patient outcome in terms of recurrence and overall survival to historical controls.

Research type: exploratory

 

“Epithelial-mesenchymal transition (EMT) markers in Hispanic Breast Cancer Patients receiving neoadjuvant (preoperative) chemotherapy and correlation with pathological response”

To assess tumors for the expression of vimentin, epidermal growth factor receptor (EGFR), and nuclear factor κ B (NF-κ B) using immunohistochemical analysis in the Hispanic population and to examine the association of these selected markers with the pathological response of the tumors.

Research type: exploratory

 

“Outcome Comparison of Radiofrequency Ablation versus Other Treatment Options for Renal Cell Carcinoma at UMC, El Paso 2008-2012”

To evaluate the oncological outcomes of radiofrequency ablation versus other therapy options such as chemotherapy, radiation or nephrectomy of renal cell carcinoma, including recurrence rate and complications in a single, tertiary care University affiliated hospital.

Research type: exploratory

 

Closed Studies

Breast Cancer

"Effect of chemotherapy on markers of metabolic syndrome in early breast cancer"

Research type: exploratory

 

"BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects"

Research type: exploratory

 

"Development of a Novel Non-Invasive Diagnostic Method for Early Detection of Breast Cancer Using Cancer Specific Volatile Organic Compounds (VOCs) in Urine"

Research type: exploratory

 

"Establishing and Testing a Breast Cancer Survivorship Program at TTUHSC-Paul L. Foster School of Medicine in El Paso”
Research type: therapeutic

 

SWOG S0927 - "A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness in Women with Early Stage Breast Cancer, Phase III"

Research type: therapeutic

 

SWOG S1202 - "A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI) - Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer”

Research type: therapeutic

 

Novartis - “A Phase II, single arm study of the use of steroid-based mouthwash to prevent stomatitis in postmenopausal women with advanced or metastatic hormone receptor positive breast cancer being treated with everolimus plus exemestane”

Research type: therapeutic

 

Gastrointestinal Cancer

Pharm-Olam - “A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Fluorouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine Pancreatic study”

Research type: therapeutic

CALGB-80802 - "Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)"

Research type: therapeutic

 

Lung Cancer

Amgen - "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbapoetin Alfa Administered at 500 micro-grams Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy."

Research type: therapeutic

 

Others

SPOC - "Banking of Tissue and Establishing Continuous Cell Lines and Xenografts from Neoplasia"

Research type: exploratory